Literature DB >> 8557897

Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease.

T Münzel1, T Heitzer, S Kurz, D G Harrison, C Luhman, L Pape, M Olschewski, H Just.   

Abstract

OBJECTIVES: We sought to examine whether long-term nitroglycerin treatment causes tolerance in large coronary arteries and whether the loss of vascular effects parallels neurohormonal adjustments.
BACKGROUND: Nitroglycerin therapy is associated with increased plasma renin activity and aldosterone levels and a decrease in hematocrit. It is assumed that nitroglycerin tolerance results in part from these neurohormonal adjustments and intravascular volume expansion.
METHODS: Three groups were studied: group I (n = 10), no prior nitroglycerin therapy; and group II (n = 10) and group III (n = 8), 24- and 72-h long-term nitroglycerin infusion (0.5 micrograms/kg body weight per min), respectively. Coronary artery dimensions were assessed using quantitative angiography. Plasma renin activity, plasma aldosterone and vasopressin levels and hematocrit were monitored before and during nitroglycerin infusions.
RESULTS: In group I, increasing intravenous concentrations of nitroglycerin caused a dose-dependent increase of the midportion of the left anterior descending coronary artery (baseline diameter 2.13 +/- 0.07 mm [mean +/- SEM], maximally by 22 +/- 2%) and left circumflex coronary artery (baseline diameter 2.08 +/- 0.07) mm, maximally by 22 +/- 3%). An intracoronary nitroglycerin bolus (0.2 mg) caused no further significant increase in diameter, indicating maximal dilation. In group II (n = 10), the baseline large coronary artery diameter under ongoing nitroglycerin was significantly larger than that in group I (left anterior descending artery 2.61 +/- 0.08 mm, left circumflex artery 2.57 +/- 0.08 mm). Additional intravenous and intracoronary nitroglycerin challenges did not cause further dilation, indicating maximally dilated vessels. At the same time, plasma renin activity, plasma aldosterone and vasopressin levels were significantly increased, and hematocrit significantly decreased. In group III patients, the baseline diameter of the left anterior descending artery and the left circumflex artery did not differ from that in patients without nitroglycerin pretreatment, indicating a complete loss of nitroglycerin coronary vasodilative effects. These patients showed no significant increase in circulating neurohormonal levels but a significant decrease in hematocrit.
CONCLUSIONS: Within 24 h of continuous nitroglycerin treatment, the coronary arteries were maximally dilated despite neurohormonal adjustments and signs of intravascular volume expansion. Within 3 days of nitroglycerin infusion, tolerance developed in the absence of neurohormonal activation. The dissociation of neurohormonal adjustments and tolerance in large coronary arteries indicates that after long-term nitroglycerin treatment, true vascular tolerance, perhaps from an intracellular tolerance step, may have developed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557897     DOI: 10.1016/0735-1097(95)00475-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Role of superoxide dismutase in in vivo and in vitro nitrate tolerance.

Authors:  T Münzel; U Hink; H Yigit; R Macharzina; D G Harrison; A Mülsch
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 2.  The physiology and pathophysiology of the nitric oxide/superoxide system.

Authors:  T Münzel; T Heitzer; D G Harrison
Journal:  Herz       Date:  1997-06       Impact factor: 1.443

Review 3.  Mechanisms underlying nitrate-induced endothelial dysfunction: insight from experimental and clinical studies.

Authors:  Ascan Warnholtz; Nikolaus Tsilimingas; Maria Wendt; Thomas Münzel
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

4.  Chronic nitroglycerine administration reduces endothelial nitric oxide production in rabbit mesenteric resistance artery.

Authors:  Tamao Yamamoto; Junko Kajikuri; Yoshimasa Watanabe; Yoshikatsu Suzuki; Kaoru Suzumori; Takeo Itoh
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

Review 5.  Management of systemic and pulmonary hypertension.

Authors:  Jerrold H Levy
Journal:  Tex Heart Inst J       Date:  2005

6.  Effects of Oral Sodium Nitrite on Blood Pressure, Insulin Sensitivity, and Intima-Media Arterial Thickening in Adults With Hypertension and Metabolic Syndrome.

Authors:  Kara S Hughan; Andrea Levine; Nicole Helbling; Steven Anthony; James P DeLany; Maja Stefanovic-Racic; Bret H Goodpaster; Mark T Gladwin
Journal:  Hypertension       Date:  2020-08-03       Impact factor: 10.190

Review 7.  Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress.

Authors:  Andreas Daiber; Thomas Münzel
Journal:  Antioxid Redox Signal       Date:  2015-09-24       Impact factor: 8.401

Review 8.  Nitrate tolerance and the links with endothelial dysfunction and oxidative stress.

Authors:  Katherine E Fayers; Michael H Cummings; Kenneth M Shaw; David W Laight
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

9.  Discovery and Clinical Evaluation of MK-8150, A Novel Nitric Oxide Donor With a Unique Mechanism of Nitric Oxide Release.

Authors:  Clayton D Knox; Pieter-Jan de Kam; Karim Azer; Peggy Wong; Antwan G Ederveen; Diane Shevell; Christopher Morabito; Alan G Meehan; Wen Liu; Tom Reynders; Jean Francois Denef; Anna Mitselos; Daniel Jonathan; David E Gutstein; Kaushik Mitra; Shu Yu Sun; Michael Man-Chu Lo; Doris Cully; Amjad Ali
Journal:  J Am Heart Assoc       Date:  2016-08-25       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.